Nutraceuticals for the treatment of metabolic diseases: Evidence from clinical practice

Giuseppe Derosa, Pamela Maffioli

Research output: Contribution to journalArticlepeer-review


The aim of this review is to describe some types of supplements that have been shown to be good co-adjuvants along with diet and drug treatment in improving insulin resistance and dyslipidemia. We can conclude that some nutraceuticals, such as l-carnitine, berberine, omega-3 polyunsaturated fatty acids, krill oil and red yeast rice, can be helpful in reducing hypercholesterolemia or insulin resistance, as reported in clinical trials. Nutraceuticals can be associated with conventional pharmacological treatments to achieve an improved lipid profile without increasing statin dosage. Similarly, although nutraceuticals cannot replace conventional antidiabetic treatments, they may be useful as an adjuvant to standard therapy, improving insulin resistance. However, not all nutraceuticals are the same and their natural origin does not mean that everyone can take them or that they cannot be dangerous; nutraceuticals should be used only under medical prescription and should be combined with a well-balanced diet.

Original languageEnglish
Pages (from-to)297-304
Number of pages8
JournalExpert Review of Endocrinology and Metabolism
Issue number3
Publication statusPublished - May 1 2015


  • berberine
  • insulin resistance
  • lipid profile
  • nutraceuticals
  • omega 3

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Nutraceuticals for the treatment of metabolic diseases: Evidence from clinical practice'. Together they form a unique fingerprint.

Cite this